LATEST ALERTS
CBD company Chanelle McCoy Health has received approval to start a trial which may allow it to sell its CBD sleeping aid as an over-the-counter (OTC) drug in Australian pharmacies
The sale and possession of CBD will be banned in Hong Kong from the beginning of February 2023 following an announcement earlier this year. Under the new rules, CBD will be classified in the same way as heroin and cocaine
In a first attempt to legalise cannabis through the federal parliament in Australia, the Greens party is in the process of drafting a law for legalisation that will be available for public consultation later this year
Canadian company Aurora Cannabis has seen continued growth in its international business thanks to an increasing presence in emerging medical cannabis markets, notably Germany, the UK, Australia and Poland
One of the first companies involved in medical cannabis is the latest bankruptcy casualty in the volatile global cannabis market – citing slower than expected sales due to more rigorous than expected regulations
CBD products may start to appear on the Australian market but it will not be due to any action taken by the newly elected Labor government, according to industry insiders and experts
The growth potential of demand for medicinal cannabis is inspiring cross-border acquisitions of pharmaceutical brands as businesses scale up to take a bigger slice of the global market
Lausanne could become the second Swiss city after Basel to launch a recreational cannabis trial this year. But while Basel’s pilot will involve just 400 participants, Lausanne is aiming for triple that number
Companies are trying new ways to reach cannabinoid customers in severely restricted Australia, but they must be careful not to fall foul of strict guidelines that separate promoting from simply informing the public about prescription goods
Clinical trials are investigating how CBD can improve menstrual health and treat conditions such as premenstrual syndrome (PMS) and perhaps even endometriosis
Scientists around the world are starting to look even further afield for potential uses of cannabis in medical applications, such as treating the symptoms of long Covid-19, Alzheimer’s-related agitation, and to alleviate the pain resulting from HIV
The US Drug Enforcement Agency (DEA) is calling for an increase in production of cannabis and psychedelics to supply federal research and clinical trials
Two new studies on the biochemistry of cannabinoids could provide answers to a puzzling question – how does the entourage effect work?
Australian medicinal cannabis firm Cann has moved quickly to maximise the benefits of its CBD Gelpell capsule technology by entering into a collaboration deal with healthcare technology firm Emyria
Canadian cannabis firm Tilray is moving in on New Zealand’s market for medical cannabis and has received the necessary approvals to launch Tilray medical cannabis products across the country
Could cannabinoids, including CBD, provide a partial solution to the growing danger of diseases becoming resistant to existing antibiotics?
There are profits to be made from selling cannabis in Europe, according to US company Curaleaf after it signed an agreement to acquire Europe’s largest vertically integrated independent cannabis company
CBD firms are making further advances into the health and wellness subcategory of the market with new product launches, distribution deals, and clinical studies underway
A push to legalise cannabis has not been successful in New Zealand, according to reports of preliminary counts
Some recent research has cast doubt on the idea that cannabis compounds may be more effective when taken together
New Zealand will go to the polls in just under two months to decide on a broad cannabis legalisation referendum that would also encompass fully legalising CBD products
Australia has unveiled a consultation on a proposal to classify CBD products as over-the-counter medications, available in pharmacies after consultation with a pharmacist
Results from a successful phase three clinical trial on the use of Epidiolex to treat drug-resistant Dravet syndrome have been published in the JAMA Neurology journal
A Denver-based chain claims to be the first CBD burger franchise in the US, while a Japanese company says it can extract CBD from orange peel. These and other stories are in CBD-Intel’s latest round-up of business news in brief
Toothpaste giant Colgate is entering the CBD market, researchers have created a laser scanner that can tell the difference between legal hemp and potentially illegal cannabis, and wrestling legend Kevin Nash has become the latest celebrity to endorse CBD, plus more
Tom Hanks refutes false claims over endorsement of CBD products, research suggests cannabinoids benefit gene receptor diseases and CBD coffee is set to hit the market, plus more
Guitar legend Carlos Santana is teaming up with a legal cannabis company to have his own branded range of CBD; a CBD firm plans to replant burnt Australian trees, and a French restaurant offers a CBD menu, plus more
CBD-Intel brings you news that a rugby league team will be the first senior outfit in its sport to promote a CBD brand on its kit, a qualification for hemp production is offered in Kentucky and a US business gains USDA organic certification, plus more
According to research from San Diego State University, CBD is the most searched health term in the US. Also covered are further stories from the US, Australia, India, Italy and Switzerland
A legal battle between a Canadian cannabis company and a US hemp company leads this round-up of business news in brief. Also covered are stories from Australia, Germany, and a number of US states
CannIntelligence.com provides independent, in-depth regulatory and market data and intelligence for the global cannabis and cannabinoid sector.
Sign up to access our business and regulatory briefings and get the most updated news, insights and our expert analysis to keep you on top of worldwide industry trends.
By signing up you agree to our Terms and Conditions Please note trial access may take up to 24 hours to be granted as access must be qualified by a member of the CBD-Intel team.
